Human recombinant monoclonal antibody against synthetic α-dystroglycan mucin: a promising tool for dystroglycanopathies diagnosis

Vol. 1, 2019. - 117943
Pôster
Favorite this paper
How to cite this paper?
Abstract

Dystroglycanopathies are muscular disorders associated to hypoglycosylation of α-dystroglycan (hgα-DG)[1]. Their diagnosis is still a critical issue since there are not specific antibodies available for hgα-DG [2]. Hence, we synthesized a hypoglycosylated α-DG mimetic glycopeptide (glycopeptide-1) to generate mouse polyclonal antibodies (IP-pAbs) and fragment of human recombinant antibodies. Variable heavy (VH) and variable light (VL) domains were selected by Phage Display, identified by NGS, and analyzed by ATTILA platform. The best-selected VH and VL domains were cloned (GpαDG1-scFv) and expressed in E. coli. IP-pAbs and GpαDG1-scFv recognized the glycopeptide-1. The peptide portion of glycopeptide-1 partially inhibited the anti-GpαDG1-scFv/glyccopeptide-1 interaction, suggesting that it involves the amino acids and the sugar portion from glycopeptide-1. In silico analysis suggested that this interaction occurs through hydrogen bonds and hydrophobic contacts involving amino acids from anti-GpαDG1-scFv with arginine-8 and α-mannose from glycopeptide-1. This work can help the development of novel strategies to dystroglycanopathies diagnosis.

Institutions
  • 1 Faculdade de Ciências Farmacêuticas de Ribeirão Preto (FCFRP), Universidade de São Paulo (USP)
  • 2 Universidade de Brasília
  • 3 Istituto di Biostrutture e Bioimmagini / Universita' degli Studi di Napoli
Track
  • Biotechnology
Keywords
α-Dystroglycan mucin
Antibody
Phage Display